ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diot, P
Right arrow Articles by Lemarie, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diot, P
Right arrow Articles by Lemarie, E
Eur Respir J 1997; 10: 1995-1998
Copyright © ERS Journals Ltd 1997

Original Articles

Nebulization and anti-Pseudomonas aeruginosa activity of colistin

P Diot, F Gagnadoux, C Martin, H Ellataoui, Y Furet, M Breteau, E Boissinot, and E Lemarie

Colistin aerosols are frequently administered to patients with cystic fibrosis. However, questions arise concerning the effect of both jet and ultrasonic nebulizers on the properties of the drug. The aim of this study was to characterize the anti-Pseudomonas aeruginosa (PA) activity of colistin after jet (Pari LL) and ultrasonic (DP100) nebulization. A bench study was performed by capturing the aerosols, determining the drug mass, and assessing its anti-PA activity. Because the inhaled mass of colistin had to be entirely recovered for the bacteriological study, it was assessed by isotopic methods, mixing the drug with a 99mTc-labelled tracer and demonstrating that 99mTc activity accurately predicted the mass of colistin. Colistin was extracted from the filters and its antibiotic activity was determined using the method employed for the study of the bacteriostatic and bactericidal power of serum on the ATCC 27853 PA strain. The postnebulization minimum inhibitory concentrations (MIC) were 1.9 micrograms.mL-1 with DP100 and 0.5 microgram.mL-1 with Pari LL. These values were less than two dilutions different from the 1 microgram.mL-1 MIC of non-nebulized colistin. We conclude that neither jet nebulization nor ultrasonic nebulization alter the antibiotic properties of colistin and that both systems can be used to nebulize colistin.


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
M. B. Shirk, K. R. Donahue, and J. Shirvani
Unlabeled uses of nebulized medications.
Am. J. Health Syst. Pharm., September 15, 2006; 63(18): 1704 - 1716.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. A. Alothman, B. Ho, M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Chest, February 1, 2005; 127(2): 522 - 529.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. L. Katz, S. L. Ho, and A. L. Coates
Nebulizer Choice for Inhaled Colistin Treatment in Cystic Fibrosis
Chest, January 1, 2001; 119(1): 250 - 255.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
C.M.B. Edwards, M.A. Cohen, and S.R. Bloom
Peptides as drugs
QJM, January 1, 1999; 92(1): 1 - 4.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.